Skip to main content
Premium Trial:

Request an Annual Quote

Illumina to Offer 3.5M Shares

NEW YORK, May 12 (GenomeWeb News) - Illumina has filed a statement with the US Securities and Exchange Commission to publicly offer 3.5 million shares of its common stock.

 

In addition, the underwriters of the offering will be granted the right to purchase an additional 525,000 shares of common stock.

 

Goldman Sachs and Merrill Lynch are acting as joint bookrunning and co-lead managers of the offering, while Cowen and Company and Robert W. Baird are acting as co-managers of the offering.

 

The company's shares were trading at $27.30 in mid-afternoon trading.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.